We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Gene Profile Predicts Risk of Bladder Cancer Recurrence

By LabMedica International staff writers
Posted on 07 Apr 2014
Print article
A genomic study has pinpointed several markers that identify bladder cancer patients at risk of recurrence and that may be indicators of overall survival status.

Nearly half of patients with bladder cancer experience recurrences, so reliable predictors of this recurrent phenotype are needed to guide surveillance and treatment. To identify genetic variants that modify bladder cancer prognosis, investigators at Dartmouth Medical School (Lebanon, NH, USA) focused on genes involved in major biological carcinogenesis processes (apoptosis, proliferation, DNA repair, hormone regulation, immune surveillance, and cellular metabolism).

The investigators analyzed genes from 563 bladder cancer patients to identify genetic variants that modify time to bladder cancer recurrence and patient survival. Patients were followed for a median of 5.4 years during which about half of them experienced at least one recurrence.

Results revealed that those patients with variants in the ALDH2 (aldehyde dehydrogenase 2) gene, which encodes an enzyme involved in alcohol metabolism, were likely to experience bladder cancer recurrence shortly after treatment. Time to recurrence was also shorter for patients who had a variant in the VCAM1 (vascular cellular adhesion molecule 1) gene, which encodes a glycoprotein involved in the development of lymphoid tissues, and were treated with immunotherapy. Patients who had noninvasive tumors and a variant in the DNA repair gene XRCC4 tended to live longer than patients who did not have the variant.

“The genetic markers that we found could potentially be useful for individually tailoring surveillance and treatment of bladder cancer patients,” said first author Dr. Angeline S. Andrew, assistant professor of community and family medicine at Dartmouth Medical School.

The study that identified biomarkers linked to bladder cancer recurrence was published in the March 26, 2014, online edition of the journal BJU International.

Related Links:

Dartmouth Medical School


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.